Literature DB >> 19736046

Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer.

Ken Yoshida1, Hideya Yamazaki, Takayuki Nose, Hiroya Shiomi, Mineo Yoshida, Mari Mikami, Tadashi Takenaka, Tadayuki Kotsuma, Eiichi Tanaka, Keiko Kuriyama, Yasunori Harada, Akira Tohda, Yutaka Yasunaga, Toshitsugu Oka.   

Abstract

PURPOSE: To introduce an effective ambulatory technique in high-dose-rate interstitial brachytherapy (HDR-ISBT) for prostate cancer, we investigated the displacement distance using our novel calculation method. METHODS AND MATERIALS: Sixty-four patients treated with HDR-ISBT as monotherapy were examined. Of these, 4, 17, and 43 patients were administered treatment doses of 38 Gy (3 days), 49 Gy (4 days), and 54 Gy (5 days), respectively. For dose administration, we used 776 flexible applicators with a removable template (ambulatory technique). Using CT images, we calculated the relative coordinates of the metal markers and applicators. From these coordinates, to analyze displacement during treatment, we measured the distance between the tip of the needle applicator and the center of gravity of the markers along the average applicator vector.
RESULTS: The median displacement distance for all applicators was 7 mm (range, -14 to 24), and that of each treatment schedule was 4, 6, and 9 mm for 38, 49, and 54 Gy, respectively. Of the 776 applicators, displacement of >10 mm was seen in 198 (26%) applicators and >15 mm in 57 (7%) applicators. Body height (p<0.0001) and anticoagulant usage (p<0.0001) were significant factors influencing displacement.
CONCLUSIONS: We investigated needle applicator displacement using our unique method. Additional cranial margins are necessary if there is no repositioning of the dwell position. CT scanning should be performed daily during treatment for checking the position of the applicator to detect and rectify the issue of displacement. Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19736046     DOI: 10.1016/j.brachy.2009.04.006

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

1.  High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates?

Authors:  Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Tadayuki Kotsuma; Mineo Yoshida; Koji Masui; Yasuo Yoshioka; Yoshifumi Narumi; Toshitsugu Oka; Eiichi Tanaka
Journal:  Strahlenther Onkol       Date:  2014-05-17       Impact factor: 3.621

Review 2.  The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.

Authors:  Yasuo Yoshioka; Ken Yoshida; Hideya Yamazaki; Norio Nonomura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2013-03-29       Impact factor: 2.724

Review 3.  High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.

Authors:  Yasuo Yoshioka; Osamu Suzuki; Yuki Otani; Ken Yoshida; Takayuki Nose; Kazuhiko Ogawa
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

4.  Effect of using different U/S probe Standoff materials in image geometry for interventional procedures: the example of prostate.

Authors:  Stefanos Diamantopoulos; Natasa Milickovic; Saeed Butt; Zaira Katsilieri; Vasiliki Kefala; Pawel Zogal; George Sakas; Dimos Baltas
Journal:  J Contemp Brachytherapy       Date:  2011-12-30

Review 5.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.